Voyager Therapeutics, Inc. (VYGR)
NasdaqGS · USD · Healthcare · Biotechnology
$1.75 (+0.57%) as of
Key statistics
- Market cap
- 107.83M
- Forward P/E
- -1.37
- EPS (TTM)
- -1.8100
- Dividend yield
- 0.00%
- 52-week range
- 1.7100 – 5.4800
- Beta
- 1.28
- Revenue (TTM)
- 34.46M
- Profit margin
- 0.00%
- Analyst target
- $14.89
- Volume
- 1.66M
About Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Lexington, MA, United States
- Employees
- 141
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.